PMID- 28304089
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20220410
IS  - 1531-4995 (Electronic)
IS  - 0023-852X (Linking)
VI  - 127
IP  - 9
DP  - 2017 Sep
TI  - Phosphorylated FADD is not prognostic for local control in T1-T2 supraglottic 
      laryngeal carcinoma treated with radiotherapy.
PG  - E301-E307
LID - 10.1002/lary.26563 [doi]
AB  - OBJECTIVE: The Fas-Associated Death Domain (FADD) gene is located in the 
      chromosome 11q13-region and frequently is amplified in head and neck squamous 
      cell carcinoma. Expression of FADD and its phosphorylated isoform (pFADD) have 
      been associated with aggressive tumor growth, lymph node metastasis, and overall 
      survival. Previously, we demonstrated that pFADD expression was related to a 
      significantly improved local control in early stage (tumor [T]1 to T2) glottic 
      laryngeal squamous cell carcinoma (LSCC). The aim of this study was to examine 
      the prognostic value of pFADD and FADD in T1 to T2 supraglottic LSCC treated with 
      primarily radiotherapy. METHODS: Tumor tissue sections of 60 patients with T1 to 
      T2 supraglottic LSCC treated with primarily radiotherapy were assessed 
      immunohistochemically for expression of pFADD and FADD. Expression percentages 
      and clinical parameters and their associations with clinical outcome were studied 
      using Cox regression and Kaplan-Meier survival analyses. Expression percentages 
      in supraglottic and glottic LSCC were compared using the Mann-Whitney U test. 
      RESULTS: Expression of pFADD and FADD in supraglottic and glottic LSCC did not 
      significantly differ. In supraglottic LSCC, both pFADD and FADD did not show 
      prognostic value for local control (hazard ratio [HR] 1.00, 95% confidence 
      interval [CI] 0.98-1.03; HR 1.03, 95% CI 0.60-1.78, respectively) and overall 
      survival (HR 0.99, 95% CI 0.98-1.01; HR 1.19, 95% CI 0.83-1.71 respectively). In 
      this cohort, lymph node status was the best predictor for local control (HR 3.73, 
      95% CI 1.30-10.67). CONCLUSION: In this homogeneous cohort of T1 to T2 
      supraglottic LSCC primarily treated with radiotherapy, lymph node status was 
      associated with local recurrence, whereas the expression of pFADD was not. LEVEL 
      OF EVIDENCE: NA. Laryngoscope, 127:E301-E307, 2017.
CI  - (c) 2017 The American Laryngological, Rhinological and Otological Society, Inc.
FAU - Wachters, Jan E
AU  - Wachters JE
AD  - Department of Pathology and Medical Biology.
AD  - Department of Otorhinolaryngology and Head and Neck Surgery.
FAU - Schrijvers, Michiel L
AU  - Schrijvers ML
AD  - Department of Pathology and Medical Biology.
AD  - Department of Otorhinolaryngology and Head and Neck Surgery.
FAU - Slagter-Menkema, Lorian
AU  - Slagter-Menkema L
AD  - Department of Pathology and Medical Biology.
FAU - Mastik, Mirjam
AU  - Mastik M
AD  - Department of Pathology and Medical Biology.
FAU - Langendijk, Johannes A
AU  - Langendijk JA
AD  - Department of Radiation Oncology.
FAU - de Bock, Geertruida H
AU  - de Bock GH
AD  - Department of Epidemiology.
FAU - Roodenburg, Jan L
AU  - Roodenburg JL
AD  - Department of Oral and Maxillofacial Surgery , University Medical Center 
      Groningen, University of Groningen.
FAU - van der Laan, Bernard F A M
AU  - van der Laan BFAM
AD  - Department of Otorhinolaryngology and Head and Neck Surgery.
FAU - van der Wal, Jacqueline E
AU  - van der Wal JE
AD  - Department of Pathology and Medical Biology.
AD  - Department of Department of Pathology, Martini Hospital, Groningen, The 
      Netherlands.
FAU - Schuuring, Ed
AU  - Schuuring E
AD  - Department of Pathology and Medical Biology.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170317
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (FADD protein, human)
RN  - 0 (Fas-Associated Death Domain Protein)
RN  - 0 (Protein Isoforms)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics
MH  - Carcinoma, Squamous Cell/*genetics/pathology/radiotherapy
MH  - Fas-Associated Death Domain Protein/*metabolism
MH  - Female
MH  - Glottis/pathology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*genetics/pathology/radiotherapy
MH  - Lymph Nodes/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*genetics/pathology/radiotherapy
MH  - Phosphorylation
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Protein Isoforms/metabolism
MH  - Regression Analysis
MH  - Statistics, Nonparametric
OTO - NOTNLM
OT  - FADD
OT  - head and neck squamous cell carcinoma
OT  - laryngeal squamous cell carcinoma
OT  - local control
OT  - overall survival
OT  - pFADD
OT  - radiotherapy
EDAT- 2017/03/18 06:00
MHDA- 2017/09/16 06:00
CRDT- 2017/03/18 06:00
PHST- 2016/08/18 00:00 [received]
PHST- 2017/01/16 00:00 [revised]
PHST- 2017/02/06 00:00 [accepted]
PHST- 2017/03/18 06:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
PHST- 2017/03/18 06:00 [entrez]
AID - 10.1002/lary.26563 [doi]
PST - ppublish
SO  - Laryngoscope. 2017 Sep;127(9):E301-E307. doi: 10.1002/lary.26563. Epub 2017 Mar 
      17.